

Medical Device Alert

Ref: MDA/2013/036 Issued: 31 May 2013 at 13:30

Device

External pacemaker:
MICRO-PACE REF 4580.

Manufactured by Pace Medical and distributed in the UK by APC Cardiovascular.



Problem	Action
<p>Update to MDA/2013/001 and MDA/2012/070 on the return to market of the MICRO-PACE REF 4580.</p>	<p>Remove from service any devices still awaiting any of the 3 modifications detailed in MDA/2012/070, until these have been completed.</p>
<h3 data-bbox="113 1281 794 1339">Action by</h3> <p data-bbox="113 1348 794 1576">All staff involved with the use of these external pacemakers.</p>	<p data-bbox="794 1272 1477 1451">Ensure continued, heightened vigilance in monitoring the safe operation of these pacemakers in use, and in reporting any new incidents to both Pace Medical and the MHRA.</p> <p data-bbox="794 1460 1477 1576">Review routine pacemaker servicing schedules, taking account of the ten year service life for all Pace Medical devices.</p>
<h3 data-bbox="113 1594 794 1653">CAS deadlines</h3>	<h3 data-bbox="794 1594 1477 1653">Contact</h3>
<p data-bbox="113 1662 794 1706">Action underway: 07 June 2013</p> <p data-bbox="113 1729 794 1774">Action complete: 14 June 2013</p>	<p data-bbox="794 1662 1477 1706">Manufacturer's authorised representative</p> <p data-bbox="794 1706 1477 1774">Steven Hanson or Catherine Rose Devices Ltd</p> <p data-bbox="794 1774 1477 1818">Tel: 01707 327 641</p> <p data-bbox="794 1818 1477 1863">Fax: 01707 266 677</p> <p data-bbox="794 1863 1477 1908">Email: pacemedicalpres@gmail.com</p>

Problem

In January 2013 the MHRA issued Medical Device Alert [MDA/2013/001](#) advising that Pace Medical had decided to cease further sales of MICRO-PACE REF 4580 external pacemakers in response to safety concerns. The MDA also gave advice on risk management for units already in use.

We have since carried out an audit of both Pace Medical's US manufacturing site and the UK authorised representative's premises. Following this audit the manufacturer provided satisfactory responses in the areas of post-market surveillance where deficiencies had been found.

Although the MHRA has received a small number of adverse incident reports involving this external pacemaker model, since our last MDA in January 2013, the manufacturer has provided sufficient feedback during our investigations to reassure us that these were not related to any new root causes. Nevertheless, clinicians should continue to closely monitor the safe operation of these devices and to report any new incidents to both the MHRA and the manufacturer.

In consultation with the MHRA, Pace Medical has now decided to resume sales of MICRO-PACE REF 4580 external pacemakers in the UK and elsewhere. We will continue to scrutinise the safety of these devices and review the appropriateness of this decision in light of any new information arising from further reported incidents, or other sources.

In addition, we have asked Pace Medical to remove all affected devices from UK hospitals which still require any one of the 3 modifications described in [MDA/2012/070](#). The company has already confirmed that they now have enough loan units available to allow this process to take place without service disruption.

Pace Medical has also recently confirmed that their products are currently sold with a [statement](#) that their expected service life is ten years from the date of purchase, and that they will not service or repair product returned after this time. Although this information was not provided when older devices were sold, they have confirmed that this condition for servicing or repair applies retrospectively to all Pace Medical devices.

Distribution

This MDA has been sent to:

- NHS trusts in England (Chief Executives)
- Care Quality Commission (CQC) (Headquarters) for information
- HSC trusts in Northern Ireland (Chief Executives)
- NHS boards in Scotland (Equipment Co-ordinators)
- NHS boards and trusts in Wales (Chief Executives)

Onward distribution

Please bring this notice to the attention of relevant employees in your establishment. Below is a suggested list of recipients.

Trusts

CAS and SABS (NI) liaison officers for onward distribution to all relevant staff including:

- A&E consultants
- Adult intensive care units
- All wards
- Cardiac laboratory technicians
- Cardiac pacing physiologists
- Cardiologists
- Cardiology departments
- Cardiology nurses
- Cardiology, directors of
- Cardiothoracic departments
- Cardiothoracic surgeons
- Cardiothoracic surgery directors
- Coronary care departments
- Coronary care nurses
- EBME departments
- Equipment stores
- Intensive care medical staff (adult and paediatrics)
- Intensive care nursing staff (adult and paediatrics)

- Intensive care units
- Intensive care, directors of
- Medical directors
- Nursing executive directors
- Paediatric intensive care units
- Purchasing managers
- Resuscitation officers
- Risk managers
- Supplies managers
- Theatre managers

Independent distribution

Establishments registered with the Care Quality Commission (CQC) (England only)

This alert should be read by:

- Hospitals in the independent sector

Please note: CQC and OFSTED do not distribute these alerts. Independent healthcare providers and social care providers can sign up to receive MDAs directly from the Department of Health's Central Alerting System (CAS) by sending an email to: safetyalerts@dh.gsi.gov.uk and requesting this facility.

Contacts

Manufacturer's authorised representative

Steven Hanson or Catherine Rose

Devices Ltd, 28 Fiddlebridge Industrial Centre, Lemsford Road, Hatfield, Hertfordshire AL10 0DE

Tel: 01707 327 641 Fax: 01707 266 677

Email: pacemedicalpres@gmail.com

England

If you are in England, please send enquiries about this notice to the MHRA, quoting reference number **MDA/2013/036** or **2012/010/004/291/003**

Technical aspects

Guido Fumagalli or Simon Holmes

Medicines & Healthcare products Regulatory Agency

Floor 4, 151 Buckingham Palace Road, London SW1W 9SZ

Tel: 020 3080 7144 or 7240 Fax: 020 8754 3965

Email: guido.fumagalli@mhra.gsi.gov.uk
simon.holmes@mhra.gsi.gov.uk

Clinical aspects

Jonathan Plumb

Medicines & Healthcare products Regulatory Agency

Floor 4, 151 Buckingham Palace Road, London SW1W 9SZ

Tel: 020 3080 6648 Fax: 020 8754 3965

Email: jonathan.plumb@mhra.gsi.gov.uk

How to report adverse incidents

Please report via our website <http://www.mhra.gov.uk>

Further information about **CAS** can be found at <https://www.cas.dh.gov.uk/Home.aspx>

Northern Ireland

Alerts in Northern Ireland will continue to be distributed via the NI SABS system.

Enquiries and adverse incident reports in Northern Ireland should be addressed to:

Northern Ireland Adverse Incident Centre

Health Estates Investment Group

Room 17

Annex 6

Castle Buildings

Stormont Estate

Dundonald BT4 3SQ

Tel: 02890 523 704

Fax: 02890 523 900

Email: NIAIC@dhsspsni.gov.uk

<http://www.dhsspsni.gov.uk/index/hea/niaic.htm>

How to report adverse incidents in Northern Ireland

Please report directly to NIAIC, further information can be found on our website <http://www.dhsspsni.gov.uk/niaic>

Further information about **SABS** can be found at <http://sabs.dhsspsni.gov.uk/>

Scotland

Enquiries and adverse incident reports in Scotland should be addressed to:

Incident Reporting and Investigation Centre

Health Facilities Scotland

NHS National Services Scotland

Gyle Square

1 South Gyle Crescent

Edinburgh EH12 9EB

Tel: 0131 275 7575

Fax: 0131 314 0722

Email: nss.irc@nhs.net

<http://www.hfs.scot.nhs.uk/online-services/incident-reporting-and-investigation-centre-irc/>

Wales

Enquiries in Wales should be addressed to:

Improving Patient Safety Team

Medical Directorate

Welsh Government

Cathays Park

Cardiff CF10 3NQ

Tel: 029 2082 3922

Email: Haz-Aic@wales.gsi.gov.uk